Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.
about
Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signalingThe lidocaine metabolite N-ethylglycine has antinociceptive effects in experimental inflammatory and neuropathic pain.Targeting glutamate synapses in schizophreniaModulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in miceThe glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects.Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.Glutamatergic targets for enhancing extinction learning in drug addictionTypical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: contribution of histamine h(1) receptor blockadeGlycine transporter 1 is a target for the treatment of epilepsy.The solute carrier 6 family of transportersMarine Ο-3 polyunsaturated fatty acids induce sex-specific changes in reinforcer-controlled behaviour and neurotransmitter metabolism in a spontaneously hypertensive rat model of ADHD.Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networksDysregulated Glycine Signaling Contributes to Increased Impulsivity during Protracted Alcohol Abstinence.Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?Abnormalities in extracellular glycine and glutamate levels in the striatum of sandy mice.The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598.The GlyT1 Inhibitor Bitopertin Ameliorates Allodynia and Hyperalgesia in Animal Models of Neuropathic and Inflammatory Pain.Schizophrenia: synthetic strategies and recent advances in drug designMultidimensional Connectomics and Treatment-Resistant Schizophrenia: Linking Phenotypic Circuits to Targeted Therapeutics
P2860
Q27023967-3DD49FD7-0E71-4654-8058-D91755D39566Q27316372-8CAF8902-0A78-434B-8E28-7AC9CB898431Q30460392-83F15B15-DBCD-4BB9-AE40-A7FCE50DBC1EQ30468003-A363A004-0585-46D7-8043-205974C766DAQ30475523-EC33C809-A0A4-4276-AE49-AD56604D6BC7Q33586550-DD6D2FA8-1270-4EB9-9DD5-CD4684AEFD12Q34381226-6EEE8442-9F17-4BD1-B988-599B0798058DQ34829339-C6D0B5AB-7CA5-45A1-B731-198EC6450720Q35966817-44B74ED2-365A-472E-BE23-120AF37687D3Q36304849-1281ECF7-E9E4-4A84-A2BC-870BF69990A3Q36346899-B641C229-11E2-4982-8CF2-65D18CB1A866Q36614190-9FFB694D-8C2A-440B-B6D8-D723803025D7Q37220392-EBFFB2EA-01D2-4E49-9E68-CCAAEC4276DFQ42320456-126201C1-741A-48D2-839A-8BE892864CC0Q42544021-64EBE978-80DA-4A8E-9ECF-1BB0996D0B16Q46049728-4B538CE7-E735-47C3-93CE-AD4758F1B063Q48874232-96FE25DF-5D08-4C8D-9153-9F535A4689D0Q49632560-D8E1CFFE-98B6-4CE4-8402-D8F3BF1FC10AQ57393544-302C1858-8F1A-400E-A665-9D98CFB4E7A9Q58698014-DBB889FB-CBA7-4850-883A-BF9732D5828E
P2860
Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Neurochemical and behavioral p ...... udal vs. cortical brain areas.
@en
Neurochemical and behavioral p ...... udal vs. cortical brain areas.
@nl
type
label
Neurochemical and behavioral p ...... udal vs. cortical brain areas.
@en
Neurochemical and behavioral p ...... udal vs. cortical brain areas.
@nl
prefLabel
Neurochemical and behavioral p ...... udal vs. cortical brain areas.
@en
Neurochemical and behavioral p ...... udal vs. cortical brain areas.
@nl
P2093
P1433
P1476
Neurochemical and behavioral p ...... udal vs. cortical brain areas.
@en
P2093
Annick J Cauvin
Beth J Hoffmann
Carrie K Jones
George E Sandusky
George G Nomikos
Harlan E Shannon
Jason Katner
John W Ryder
Julie F Falcone
P304
P356
10.1016/J.NEUROPHARM.2008.06.016
P577
2008-06-17T00:00:00Z